Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | BPTF | Q12830 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036989 | 0.89 | DPP4 (0.46) | DPP4NOTUMCHRNA7DRD2SIGMAR1 | |
| SCHEMBL10177533 | 0.89 | DPP4 (0.46) | DPP4NOTUMCHRNA7DRD2SIGMAR1 | |
| SCHEMBL424881 | 0.89 | CHRNA7 (0.55) | DPP4CHRNA7DRD2SIGMAR1MBTD1 | |
| SCHEMBL24434711 | 0.84 | CHRNA7 (0.48) | DPP4NOTUMCHRNA7BPTFDRD2 | |
| SCHEMBL10213622 | 0.84 | ADRB1 (0.43) | DPP4BPTFL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1983505 | 0.84 | USP30 (0.40) | DPP4NOTUMBPTFL3MBTL1KDM4E | |
| SCHEMBL12993239 | 0.82 | NOTUM (0.51) | NOTUMBPTFDRD2HRH3ALDH1A1 | |
| SCHEMBL12045684 | 0.82 | MAPT (0.50) | DPP4BPTFL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL3536125 | 0.82 | NOTUM (0.47) | DPP4NOTUMCHRNA7BPTFMBTD1 | |
| SCHEMBL17297914 | 0.82 | HRH3 (0.56) | CHRNA7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | DPP4 1873/4885NOTUM 3873/4885CHRNA7 2200/4885 |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | DPP4 2192/4885NOTUM 2712/4885CHRNA7 2567/4885 |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | ENPP2, NMT2, NMT1 | DPP4 1094/4885NOTUM 116/4885CHRNA7 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.